Allurion Technologies

ALUR · NYSE

$0.475−$0.46 (−49.20%)TodayMarket closed · Oct 20, 2:36 PM ET

No price history for this range.

About ALUR

Allurion Technologies, Inc. develops treatments for obesity. The company is headquartered in Natick, Massachusetts and currently employs 38 full-time employees. The company went IPO on 2021-03-29. The firm offers Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Balloon is swallowed as a capsule under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia. The Allurion Balloon is a procedure-less intragastric balloon that does not require any surgery, endoscopy, or anesthesia for placement. The balloon is swallowed in a capsule during a discrete outpatient office visit that takes approximately 15 minutes (though times may vary across different outpatient offices). The Allurion Virtual Care Suite is a cutting-edge digital therapeutic that combines AI-powered remote patient monitoring tools with a behavior change program.

Employees: 40
Headquarters: Natick, Massachusetts
Listed: Mar 29, 2021
Sector: Consumer Discretionary
Industry: Diversified Consumer Services
Website: allurion.com

Leadership

Allurion Technologies executives
Name	Title	Since	Age
Omar Ishrak	—	2021	66
Joshua Fink	—	2021	44
Jean Nehme	—	2021	37
Osama Alswailem	—	—	55
Hani Barhoush	—	—	46
Michael Harsh	—	—	67
Gwendolyn Watanabe	—	—	50

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.